Sanofi (SNY) has announced the immediate adoption of FDA-selected influenza strains for manufacturing its vaccine portfolio for the 2025-26 flu season in the US. The selected strains match those already in production by the company.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,